The bill proposes amendments to the Federal Food, Drug, and Cosmetic Act to introduce measures that allow for the temporary importation of drugs. This importation can last up to three years if a drug is determined to have a shortage. The bill also defines what constitutes a 'marginally competitive market' and establishes a protocol for expediting the review of applications related to such drugs, potentially increasing the overall availability of essential medications by encouraging more manufacturers to enter the market.
Summary
SB845, also known as the 'Short on Competition Act,' is designed to facilitate the expedited approval of generic prescription drugs and permit the temporary importation of pharmaceuticals during periods of significant drug shortages or in marginally competitive drug markets. It aims to address the accessibility of medications by ensuring that generic alternatives are made available more rapidly, which could help mitigate the impacts of shortages and reduce prices for consumers.
Contention
While the bill is aimed at improving access to medications, there may be points of contention to consider. Critics may raise concerns regarding the safety and efficacy of imported drugs, questioning whether the expedited processes could compromise regulatory standards. Additionally, pharmaceutical companies could express apprehension about increased competition and its potential impact on profit margins. The balance between ensuring availability and maintaing drug safety standards is likely to be a focal point in discussions surrounding the legislation.